Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Provided By GlobeNewswire
Last update: Feb 25, 2025
Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of SIL-204 administered subcutaneously in clinically relevant pancreatic cancer models.
Read more at globenewswire.com0.9505
-0.01 (-0.99%)
Find more stocks in the Stock Screener
SLXN Latest News and Analysis
a day ago - ChartmillThese stocks that are showing activity before the opening bell on Monday.The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
4 days ago - ChartmillFriday's after hours session: top gainers and losersWondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
8 days ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
